Bruker Launches Revolutionary timsOmni TM Mass Spectrometer
BALTIMORE--(BUSINESS WIRE)--For the 73 rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (Nasdaq: BRKR) announced the launch of the timsOmni™ system, a transformative new timsTOF-based mass spectrometer designed for scientific, drug discovery, and clinical researchers, as well as for advanced QC on biologics, offering deep structural insights into the functional or pathological proteoforms or oligonucleotides. Multimodal eXd trapping with precise electron energy control, ion accumulation, and reaction time regulation is a cornerstone innovation of the timsOmni™ platform. This also enables CIU, further expanding the value of proteoform CCS information, followed by multiple electron-based (ECD, EID) and collision-based (CID) fragmentation techniques. The timsOmni uniquely enables protein researchers and biologics developers to tailor information-rich dissociation pathways for deeper insights - with high speed and high sensitivity.
The 'Swiss-army knife' type flexibility of the timsOmni top-down capability enables the identification of low-abundant, aberrant proteoforms, the structurally altered versions of proteins arising from genetic mutations, alternative splicing, or post-translational modifications that deviate from normal physiological forms, disrupting protein function, misfolding, or aggregation, and often play critical roles in the onset and progression of human diseases, including cancer, neurodegeneration, cardiovascular disorders, and autoimmune conditions.
Anders Giessing, PhD, Science Manager at Novonesis in Denmark, said, 'We use intact protein mass analysis to ensure performance, stability, and consistency of our diverse protein product portfolio. Introduction of the timsOmni, with its Swiss Army knife versatility, redefines intact mass and top-down analysis with the precision, speed, and confidence needed to provide definitive analytical support in the development and production of industrial enzymes.'
The Omnitrap's signature high-sensitivity, high-speed, multimodal eXd capability is particularly powerful for mapping PTMs, such as histone proteoforms (H3:1K14ac) that play a crucial role in regulating gene expression by altering chromatin structure and controlling access to the DNA. Other PTMs like glycosylation critically influence protein folding, stability, transport, and cell signaling interactions, and detailed top-down or middle-down sequencing of complementarity-determining regions (CDRs) in humoral and therapeutic antibodies are important in cancer, autoimmunity and biologics development.
Prof. Albert Heck, Professor of Chemistry and Pharmaceutical Sciences at Utrecht University and Scientific Director of the Netherlands Proteomics Center, commented, 'Proteomics will finally go 'protein-centric' by using the timsOmni. The multimodal eXd capability allows for comprehensive ion sequence ladders that are ideal for de novo sequencing and human plasma antibody repertoire profiling. Analyzing and monitoring circulating antibody levels is critical for characterizing the progression of a disease, identifying patients with delayed symptom onset, and predicting potential long-term immunity.'
Frank H. Laukien, Ph.D., the CEO of Bruker Corporation, added, 'The timsOmni is a new lamppost for functional protein science, shining a light on functional and pathological proteoforms and truly enabling a new protein science paradigm for fundamental cell and molecular biology, signal transduction, cancer, neurodegeneration, and other disease research. The timsOmni will also be extremely valuable for biopharma drug discovery and development, as well as for biologics QC analysis, from therapeutic antibodies to antibody-drug conjugates.'
The timsOmni is supported by OmniScape™, Bruker's next-generation top-down proteomics software that features state-of-the-art algorithms for de-isotoping complex spectra, automated charge state assignment, de novo protein sequencing support, and sequence confirmation. These key features provide unrivaled benefits for the accurate identification of proteoforms, post-translational modifications, and non-canonical proteins. OmniScape transforms complex eXd fragmentation spectra into actionable biological insights—empowering researchers to navigate the new world of functional proteoformics.
Prof. Ole N. Jensen, Group Leader at the Protein Research Group of the University of Southern Denmark, observed, 'The timsOmni technology and OmniScape software already impacted our strategies for intact protein and proteoform analysis. Multimodal MS/MS fragmentation and MS3 afford very high amino acid sequence coverage and accurate localization of post-translational modifications in histones.'
The timsOmni comes with the new NEOS off-line nanoESI for the extremely low infusion flow rates required for the study of protein complexes, allowing for extended analysis of scarce samples. The NEOS source works with coated and non-coated emitters. Additionally, the timsOmni retains the high sensitivity of the timsTOF Ultra 2 for nLC dia-PASEF high-throughput bottom-up 4D-proteomics.
The timsOmni ushers in a new era of functional proteomics, setting the stage for landmark discoveries in ' Proteoformics ', and advancing a transformative new paradigm in protein research as it illuminates protein function through the deep sequencing of proteoforms, humoral and multi-specific antibodies, and other complex biomolecules.
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Should PayPal be on my list of shares to buy?
On the face of it, PayPal (NASDAQ:PYPL) ought to be on my list of shares to buy. The company has a market value of $69bn and has generated just under $6bn in free cash in the last year. With minimal debt, that implies a free cash flow yield of almost 9%. That's pretty high considering the business isn't in decline – but there's a catch when it comes to the valuation. With no dividend, PayPal returns cash to shareholders via share buybacks. These work by reducing the outstanding share count, increasing the value of each of the remaining shares. Since 2020, PayPal's returned over $20bn via share repurchases. That's around 30% of its current market value and the returns have been going up. Year Share Buybacks 2024 $6bn 2023 $5bn 2022 $4.2bn 2021 $3.4bn 2020 $1.6bn Despite this, the company's share count has only fallen by about 13% over the last five years. That's much less impressive and it raises an important question for investors. PayPal's share count isn't really going down much despite the firm using almost all the free cash it generates to buy back shares. So where's the money going? A big part of the answer is stock-based compensation. This is where PayPal issues shares to pay its staff part of their salaries in the firm's stock, rather than cash. A lot of companies do this and I don't think there's anything intrinsically wrong with it. But it's something that investors need to factor into their calculations. Since 2020, PayPal's issued around $6.5bn in stock to cover these expenses. And this has gone some way towards offsetting the cash the firm's been using for share buybacks. In 2024, the company spent almost $6bn on repurchasing shares, but just over 20% of this was offset by stock-based compensation. So the outstanding share count only fell by around 6%. Stock-based compensation doesn't involve cash leaving the business directly. As a result, some investors tend to think it isn't a real expense. I however, think this is a mistake. Issuing equity automatically reduces the value of share buybacks and this is a key mechanism companies can return cash to shareholders. This is especially true when it comes to PayPal. Its 9% free cash flow yield's attractive at first sight, but the firm can't just use this to bring down its share count by that amount every year. Before it can start bringing down its number of shares outstanding, it has to buy back the ones it issued. And it has to do that with cash, making it a very real expense for investors. I don't think PayPal's stock-based compensation is a reason to dismiss the stock out of hand immediately. And the company's undergoing an interesting shift in terms of its priorities. Focusing on margins over revenue growth could boost profits and integrating further into the online transaction process could boost its competitive position. These are potential positives. For the time being though, I think there are better opportunities available. While the stock looks like a bargain at first sight, I don't think it's as attractive for me as it seems. The post Should PayPal be on my list of shares to buy? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has recommended PayPal. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Yahoo
Meta Platforms (META) Unveils Advanced AI Model Focused on Physical Reasoning
Meta Platforms, Inc. (NASDAQ:META) is one of the best stocks to buy. On June 11, Meta rolled out V-JEPA 2, a refined AI model that strengthens the system's capacity to understand and predict physical gestures. The newly introduced model empowers robots and intelligent agents with stronger situational awareness and predictive skills, crucial for fostering AI systems that "think before they act." By analyzing video footage, the model developed an understanding of real-world patterns, such as human-object contact, kinetic movement, and inter-object interactions. Testing in Meta's research facilities confirmed the model could guide robots in executing actions like reaching for, lifting, and placing items elsewhere. Three new benchmarks have been released by Meta to help measure the effectiveness of current models in interpreting real-world interactions via video. By sharing these benchmarks, Meta hopes to accelerate progress in the AI research community. Meta underlined the importance of physical reasoning as a cornerstone for equipping AI systems to interact effectively with the tangible world and to attain higher levels of artificial intelligence. While we acknowledge the potential of META as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Insider
3 hours ago
- Business Insider
TruGolf Announces Reverse Stock Split
Salt Lake City, Utah, June 18, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading provider of golf simulator software and hardware, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of its Class A common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 23, 2025, and the Company's Class A common stock will open for trading on The Nasdaq Capital Market on June 23, 2025 on a post-split basis, under the existing ticker symbol 'TRUG' but with a new CUSIP number 243733409. As a result of the reverse stock split, every fifty shares of the Company's Class A common stock issued and outstanding prior to the opening of trading on June 23, 2025 will be consolidated into one issued and outstanding share. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company's equity incentive plans. The Class A common stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Class A common stock or the par value of the Class A common stock. No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would become entitled to a fractional share because the number of shares of Class A common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, the stockholder will be entitled to receive a cash payment in lieu of a fractional share. As a result of the reverse stock split, the number of shares of Class A common stock outstanding will be reduced from approximately 40.5 million shares to approximately 0.8 million shares, and the number of authorized shares of Class A common stock will remain at 650 million shares. About TruGolf, Inc. Since 1983, TruGolf has been passionate about driving the golf industry with innovative indoor golf solutions. TruGolf builds products that capture the spirit of golf. TruGolf's mission is to help grow the game by attempting to make it more Available, Approachable, and Affordable through technology - because TruGolf believes Golf is for Everyone. TruGolf's team has built award-winning video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT. Since TruGolf's beginning, TruGolf has continued to attempt to define and redefine what is possible with golf technology. Forward-Looking Statements This news release contains certain statements that constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements that are not of historical fact constitute 'forward-looking statements' and accordingly, involve estimates, assumptions, forecasts, judgements and uncertainties. Forward-looking statements include, without limitation, the timing of the reverse stock split. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC's website,
